REGULATION BRIEFING

Urban Wastewater Treatment Directive: The Polluter-Pays Levy Testing EU Generics

The recast Urban Wastewater Treatment Directive (UWWTD) adds a fourth treatment stage to Europe’s sewage plants to strip out drug and cosmetic residues, and makes medicine and cosmetics producers pay at least 80% of the bill. Member states must write it into national law by July 31, 2027. An EU Advocate General has now told the Court of Justice that the cost split rests on flawed evidence.

Urban Wastewater Treatment Directive: latest updates

  • Sep 3, 2026: Advocate General Juliane Kokott recommended that the Court of Justice annul the 80% producer-pays provisions in Poland’s case (C-193/25). The judgment is pending.
  • Jun 18, 2026: The European Parliament voted 294 to 245 to ask the Commission to pause the producer-pays scheme and deliver a new impact assessment by the end of 2026. Commissioner Jessika Roswall rejected a pause.
  • May 2026: Ireland’s High Court referred an industry challenge from the Irish Pharmaceutical Healthcare Association and Medicines for Ireland to the Court of Justice.
  • Feb 18, 2026: The EU General Court dismissed direct challenges from EFPIA, Cosmetics Europe and several drugmakers as inadmissible, without ruling on the merits.

Urban Wastewater Treatment Directive at a glance

RegionEuropean Union
InstrumentDirective (EU) 2024/3019, recast Urban Wastewater Treatment Directive
In forceJanuary 1, 2025
Who paysProducers placing human medicines or cosmetics on an EU market, including importers
Cost shareAt least 80% of quaternary treatment investment and operating costs; member states can set it higher
Legal statusIn force; producer-pays scheme under legal challenge
Key dateTransposition deadline July 31, 2027; national producer-pays schemes running by December 31, 2028
Most exposedMarketing authorization holders for low-margin generics, and the API and CDMO partners that supply them
Official sourceEUR-Lex
PharmaSource Score252 (rank 8)
Impact 6, Reach 7, Likelihood 6
Download the PharmaSource Regulatory Radar

What the Urban Wastewater Treatment Directive is

Conventional sewage plants remove solids, organic matter and nutrients, but traces of painkillers, antibiotics and other drugs pass through into rivers. The recast directive tackles them with a fourth, “quaternary” stage, typically ozonation or activated carbon, phased in at larger plants through 2045. It funds that stage with extended producer responsibility (EPR), which applies the EU’s polluter-pays principle.

The directive works through five levers:

  • Quaternary treatment: Larger plants must add micropollutant removal on a fixed schedule to 2045.
  • Producer pays: Article 9 makes producers of human medicines and cosmetics cover at least 80% of the costs, from construction to operation. Member states can push that share to 100%.
  • Two sectors only: The Commission’s impact assessment found the two sectors account for about 92% of the relevant micropollutants, so no other industry pays.
  • National schemes: Each member state sets up producer responsibility organizations that collect fees based on the quantity and hazard of products sold.
  • Imports included: The rule covers every medicine on an EU market, wherever it is made.

Where the Urban Wastewater Treatment Directive stands

  • January to March 2025: The directive enters into force. EFPIA and Cosmetics Europe challenge it at the General Court, and Poland files for annulment at the Court of Justice.
  • December 2025: The Commission’s Joint Research Centre publishes an updated cost study, which finds EU-wide costs within the range of the 2022 impact assessment. The Commission’s environmental omnibus leaves the directive untouched.
  • February 2026: The General Court dismisses the industry cases for lack of standing.
  • June 2026: Parliament calls for a pause; the Commission defends the law.
  • September 2026: The Advocate General backs Poland on the cost split.

The Advocate General’s opinion is the strongest blow so far. Kokott found serious methodological flaws in how the toxic load was calculated, questionable data for some drug substances and too little attention to other pollution sources. She proposed annulling Article 9(1)(a) and Annex III, but she did not reject producer responsibility as a tool. The Court often follows its Advocates General, though it is not bound to.

What the Urban Wastewater Treatment Directive means for manufacturing and outsourcing

The fees fall on the company that places a medicine on the market, so the first hit lands on marketing authorization holders. The damage then travels down the supply chain. Elisabeth Stampa of Medicines for Europe told CDMO Live that a month of diabetes or hypertension treatment can cost less than a coffee, and that adding 50 cents “possibly that product is going to be withdrawn.” The exposure differs by company:

  • Generics makers: Regulated prices and tenders leave little room to pass fees on. Products near zero margin face withdrawal, and EFPIA warns that companies locked into long-term fixed-price contracts must absorb the cost.
  • Innovative sponsors: Higher prices absorb the fees more easily, but high-volume products and those with persistent or toxic actives will carry larger bills once fees are weighted by hazard.
  • API makers and CDMOs: These companies pay no fee unless they hold the marketing authorization, but they lose volume when generics exit and face tougher price talks from customers trying to recover costs.
  • Manufacturing sites: The directive targets municipal plants, but sites discharging to sewers may face pressure to treat effluent on site, alongside obligations under the Industrial Emissions Directive.
  • Non-EU producers: Imports pay the same fees, so moving production offshore avoids none of them.

For outsourcing leaders, the practical step is to model EU fee exposure by product and country, flag low-margin generics at risk of withdrawal, and check which supply contracts allow cost pass-through.

Why supporters back the Urban Wastewater Treatment Directive

“Such cost adaptation per se would not challenge the conclusions of the impact assessment.”

European Commission Joint Research Centre, updated cost study, via EU Perspectives
  • Polluter pays: Supporters argue the sectors whose products leave residues should fund their removal, ahead of taxpayers.
  • Modest per-person cost: Roswall told Parliament the Commission’s latest figures put removal costs at €2.70 to €3.20 per citizen a year by 2045.
  • Households protected: Water operators’ group EurEau says the scheme stops local businesses, farmers and households from bearing the full cost.
  • Greener products: Fees weighted by hazard reward companies that design actives and processes that break down more easily.
  • Industry adapts: Elena Barboni of Flamma told CDMO Live that sustainability investment can give a CDMO “the differentiation with other companies.”

Criticisms of the Urban Wastewater Treatment Directive

“Pharmaceuticals and cosmetics have been singled out … which is absolutely disproportionate.”

Neha Dave, EU Government Affairs Advisor, speaking to the PharmaSource Podcast
  • Other sources pay nothing: Many industries release micropollutants, but only two sectors pay. The Advocate General found other sources were given too little weight.
  • Weak evidence: Industry argues the toxic-load calculation misallocated substances to the two sectors, a point the Advocate General’s opinion now supports.
  • Costs underestimated: Industry groups say national analyses show the Commission underestimated costs by 300 to 600%.
  • Medicine supply: Parliament asked for the impact on generic and critical medicines to be assessed, a gap health officials in several member states have also raised.
  • Clash with the Critical Medicines Act: Brussels is paying to keep generics production in Europe while adding a cost that pushes the lowest-margin products out. Stampa warned that without price incentives, “the European manufacturers will end up selling the products outside the European Union again.”
  • Legal uncertainty: Producers must prepare for national schemes while the core provision may be annulled.

What’s next for the Urban Wastewater Treatment Directive

  • Court of Justice judgment: The ruling in C-193/25 decides whether Article 9(1)(a) survives. No date is set. The Irish referral runs behind it.
  • Commission response: Parliament asked for a new impact assessment by the end of 2026. The Commission has so far stood by its cost study.
  • July 31, 2027: Member states must transpose the directive. Watch how each sets fee formulas and whether any exceed the 80% floor.
  • December 31, 2028: National producer-pays schemes must be running.
  • Our score: Impact 6, Reach 7, Likelihood 6, giving 252 and rank 8. If the Court follows the Advocate General, the 80% rule falls and Likelihood drops sharply.

Related articles

Tracking global policies and their impact on biopharma manufacturing
REGULATORY RADAR
Full tracker of regulation changing biopharma manufacturing and supply.
Free to access and updated daily.